Skip to main content
. 2006 Jul 11;108(9):2942–2949. doi: 10.1182/blood-2006-05-021782

Table 3.

Outcome of treatment

Before CTL evaluation
Fold reduction in EBV load
Outcome at 1 y
Patient EBV DNA load PTLD CTL dose Toxicity 2 mo after 6 mo after Clinical EBV DNA load
1 4 156 No 2 × 107/m2 No 2.3 0.7 Well 1 500
2 136 000 No 2 × 107/m2 No 0.6 3 Well 180 000
3 4 506 No 2 × 107/m2 Transient rise in AST* 2.5 3.7 Well 400
4 16 204 No 5 × 107/m2 No 0.1 1 Well 15 000
5 10 172 No 5 × 107/m2 No 0.4 1.3 Well 3 900
6 6 704 No 5 × 107/m2 No 0.6 10 Well 1 100
7 4 938 No 1 × 108/m2 No 0.9 0.6 Well 3 900
8 14 002 No 1 × 108/m2 No 0.6 0.9 Well 7 200
9 2 500 No 5 × 107/m2 × 3 No 1.7 10 Well 7 000
10 1 100 No 5 × 107/m2 × 3 No 2.7 10 Well < 400
11 1 500 No 5 × 107/m2 × 4 No 0.4 1.2 Well 700
12 20 900 Eye 5 × 107/m2 × 4 No 0.8 3 Well 25 000
*

Two months after CTL infusion.

PTLD decrease in size.